Treatment and prevention of hand-foot skin reaction — dermatological adverse effect of regorafenib (literature review)

Regorafenib is an agent of targeted cancer therapy, that is a multikinase inhibitor of angiogenesis, oncogenesis, microenvironment and tumor immune system. Due to the unique mechanism of action, regorafenib is highly effective in the treatment of various tumors. The most common adverse event associated with regorafenib, leading to a dose reduction or its cancellation, is a manifestation of skin toxicity — hand-foot skin reaction. The review compiles published data based on research and experience in managing this dermatological adverse event. Adequate staff and patient awareness, monitoring, prevention, and treatment are necessary to reduce the incidence, duration, and severity of hand-foot skin reaction associated with regorafenib. Determining the optimal management for patients with this complication becomes an essential component of the complex treatment of patients receiving regorafenib anti-tumor therapy, especially considering the fact that hand-foot skin reaction is a marker of its effectiveness.